Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
Date:2/27/2013

million during the three months and year ended December 31, 2011, respectively. The decrease is due to the introduction of generic vancomycin.

Cost of sales increased for the three months and year ended December 31, 2012 primarily due to the effect of continuing growth of Cinryze and the royalty due to Genzyme for Vancocin sales which was not payable in 2011.

Research and development costs incurred during 2012 were relatively flat compared to 2011 as the increased spending during 2012 in our various programs was offset by upfront and license payments of $15.5 million to Halozyme and a $3.0 million license payment to Intellect Neurosciences in 2011. The increase in selling, general and administrative expenses in the year ended December 31, 2012 compared to the year ended December 31, 2011 was driven by the growth of our global organization and our commercialization efforts.

We incurred other operating expenses of $8.7 million in the year ended December 31, 2012 compared to $8.5 million in the year ended December 31, 2011.  During 2012, we recognized $4.5 million of expense due to the re-measurement of the fair value of the contingent consideration and $3.7 million of start-up cost paid to suppliers. Results for 2011 included $4.7 million of expense due to the re-measurement of the fair value of the contingent consideration, $3.4 million of costs to expand Cinryze manufacturing capacity at Sanquin and an $8.5 million impairment charge related to certain assets acquired from Auralis. 

Our tax expense for the quarter was $2.5 million and $13.4 million for the year versus $10.2 million and $67.3 million for the respective prior year periods.  Our effective tax rate for 2012 was 71 percent up from 32 percent for the previous year.  The effective tax rate for 2012 was impacted by approximately 170 basis points due to the recording of a valuation allowance related to certain state net operating losses. 

Wo
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. ViroPharma To Participate In The JMP Securities Healthcare Conference
4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
11. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... CHAPEL HILL, N.C. , Oct. 17, 2014 ... key insights is a critical success factor in ... companies must develop market research organizations that effectively ... their location, specialty or service area. ... groups create value and earn recognition from internal ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US ... a leading online community and information resource for neurologists and ... and Alzheimer disease , with discussions of the ... 1 million Americans have Parkinson disease , more than ... or Lou Gehrig disease. Diagnosis can be difficult ...
(Date:10/17/2014)... 17, 2014 According ... by Technique (Optical Coherence Tomography, Hyperspectral Imaging, ... (Ophthalmology, Neurology, Oncology, Cardiology) - Global Forecasts ... the Optical Imaging market over the forecast ... at $917.1 million in 2014 and is ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4
... Calif., Feb. 8, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... to treat serious diseases associated with abnormal auto-immune responses ... Rosania to the position of Vice President of Global ... for developing global regulatory strategies and managing all aspects ...
... 2011 Genomic Health, Inc. (Nasdaq: GHDX ) ... ended December 31, 2010. Total revenue for the ... with $149.5 million in 2009, an increase of 19 percent. ... 31, 2010, compared with $146.6 million in 2009.  Contract revenue ...
Cached Medicine Technology:Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance 2Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance 3Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 2Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 3Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 4Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 5Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 6Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 7Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 8Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 9
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Sit and Slim II . , The ... use Sit and Slim II because it contains Sibutramine ... weight loss product on various websites and possibly in some ... for safety reasons, can significantly increase blood pressure and/or pulse ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Startâ„¢ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... -- Patients who are prescribed higher doses of opioid painkiller ... of death from overdose than those given lower doses, a ... the April 6 issue of the Journal of the ... who take opioid painkillers both as-needed and as regularly scheduled ...
... H5N1 avian influenza in endemic regions can largely be blamed ... poultry products and caged birds, and movement of wild birds ... outbreaks of avian influenza have suggested strong evidence of migratory ... distances. In a paper published last week in ...
... April 5 (HealthDay News) -- No doubt timed to coincide with ... detailing a trendy new diet made famous by the French is ... The Dukan Diet has sold more than 3 million ... is publishing the book here. Created by French physician Dr. ...
... Rockville, Md., April 5, 2011In the growing global battle ... of Medicines (PQM) program has launched a new, public ... stakeholders from countries in Africa, South America and Southeast ... access to the internet, the Medicines Quality Database (MQDB) ...
... TUESDAY, April 5 (HealthDay News) -- The inner ear can actually ... vibrations in the inner ear continue even after a sound has ... The study is published in the April 5 issue of ... the investigators found that after-vibrations in the inner ear were dependent ...
... Thousands of physicians, researchers and academics from around the ... Digestive Disease Week (DDW), the premiere scientific conference in ... Each day of the conference will feature ... gastrointestinal health issues, including: Does ...
Cached Medicine News:Health News:Patients on Higher Doses of Prescription Painkillers More Apt to Overdose 2Health News:Migratory birds, domestic poultry and avian influenza 2Health News:Migratory birds, domestic poultry and avian influenza 3Health News:Can the Dukan Diet Do It? 2Health News:Can the Dukan Diet Do It? 3Health News:New database to help track quality of medicines in global markets 2Health News:New database to help track quality of medicines in global markets 3
Castroviejo colibri tying forceps with 5 mm tips and 5 mm titanium coated platforms. Length 110 mm....
Tennant angled tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano straight tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Medicine Products: